Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases

doi:10.3748/wjg.v22.i11.3127

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9881)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-7) series.

Item

Count

PDF

1082

WORD

313

HTML

6489

Tables (1-7)

248

Sum=8132

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

656

Download

1093

Sum=1749

Mar 21, 2016 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Mar 21, 2016; 22(11): 3127-3149
Published online Mar 21, 2016. doi: 10.3748/wjg.v22.i11.3127

Table 1 Chemotherapy for advanced or metastatic disease (NCCN and ESMO guidelines)

Options for	Options for therapy	Options for therapy
Initial therapy	After first progression	After second progression
FOLFOX +/- bmab or cetux/pmab¹	Irinotecan +/- bmab or aflib or cmab/pmab¹	Irinotecan + cmab or pmab¹
CAPOX +/- bmab or cmab/pmab¹	FOLFIRI +/- bmab or aflib or cmab/pmab¹	Regorafenib
		Clinical trial
		Best supportive care
FOLFIRI +/- bmab or cmab/pmab¹	FOLFOX +/- bmab	CAPOX
	CAPOX +/- bmab	FOLFOX
	Irinotecan + cmab/pmab¹	Irinotecan + cmab/pmab¹
		Regorafenib
		Clinical trial
		Best supportive care
Bmab + 5-FU/LV or Cape or FOLFOXIRI	Bmab + FOLFOX/FOLFIRI/Irinotecan/CAPOX	Irinotecan + cmab/pmab1
	Bmab + Irinotecan + Oxaliplatin	FOLFOX
	Aflib + FOLFIRI/Irinotecan	CAPOX
	Irinotecan + cmab/pmab¹	Regorafenib
	Regorafenib

¹(KRAS/NRAS WT gene only). Bmab: Bevacizumab; Cape: Capecitabine; Cmab: Cetuximab; Pmab: Panitumumab; Aflib: Aflibercept.

Citation: Sag AA, Selcukbiricik F, Mandel NM. Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. World J Gastroenterol 2016; 22(11): 3127-3149
URL: https://www.wjgnet.com/1007-9327/full/v22/i11/3127.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i11.3127